Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 9/20 | 0.54 |
| ▸ | CTSL | P07711 | 6/20 | 0.54 |
| ▸ | CTSB | P07858 | 4/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 7/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8493861 | 0.86 | CTSS (0.55) | CTSSCTSLCTSBPSMB8PSMB5 | |
| SCHEMBL6671871 | 0.86 | CTSS (0.55) | CTSSCTSLCTSBPSMB8PSMB5 | |
| SCHEMBL6078490 | 0.86 | SYK (0.56) | CTSSCTSLCTSBADORA3ADORA2A | |
| SCHEMBL6078485 | 0.86 | SYK (0.56) | CTSSCTSLCTSBADORA3ADORA2A | |
| SCHEMBL10904441 | 0.86 | CTSK (0.69) | CTSSCTSLCTSBCTSK | |
| SCHEMBL30312639 | 0.84 | CTSS (0.57) | CTSSCTSLCTSBSYKCTSK | |
| SCHEMBL7886596 | 0.84 | CTSS (0.52) | CTSSCTSLCTSBSYKCTSK | |
| SCHEMBL17756116 | 0.83 | CTSK (0.53) | CTSSCTSLCTSBSYKCTSK | |
| SCHEMBL11927650 | 0.83 | SMN1; SMN2 (0.49) | CTSSCTSLCTSBSYKCTSK | |
| SCHEMBL6178945 | 0.83 | SYK (0.55) | CTSSCTSLCTSBSYKCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132776-A1 | Inhibitors of transglutaminase | N-ZYME BIOTECH GMBH (DE) | 2002-09-19 | — | — | US | disclosed |
| WO-2002036798-A2 | INHIBITORS OF TRANSGLUTAMINASES | N-ZYME BIOTEC GMBH (DE) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132776-A1 | Inhibitors of transglutaminase | TGM2, GNMT, TGM1 | CTSS 1533/4885CTSL 1518/4885CTSB 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.